Cardiovascular co-morbidity in rheumatic diseases by Turesson, Carl et al.
© 2008 Turesson et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2008:4(3) 605–614 605
REVIEW
Cardiovascular co-morbidity in rheumatic 
diseases
Carl Turesson1,2
Lennart TH Jacobsson1
Eric L Matteson2
1Department of Rheumatology, Malmö 
University Hospital, Malmö, Sweden; 
2Division of Rheumatology, Mayo 
Clinic College of Medicine, Rochester, 
MN, USA
Correspondence: Carl Turesson
Department of Rheumatology, Malmö 
University Hospital, Södra Förstadsgatan 
101, S-205 02 Malmö, Sweden
Tel +46 40 332 419
Fax +46 40 337 018
Email turesson.carl@mayo.edu
Abstract: Patients with rheumatic disorders have an increased risk of cardiovascular disease 
(CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease 
severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic 
disorders include immune dysregulation and inﬂ  ammatory pathways, which are potential tar-
gets for therapy. Lessons from RA and SLE may have implications for future research on the 
pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppres-
sion of inﬂ  ammation reduces the risk of CVD morbidity and mortality in patients with severe 
RA. The modest, but clinically relevant, efﬁ  cacy of atorvastatin treatment in RA adds to the 
evidence for important anti-inﬂ  ammatory properties for statins. There is increased recogni-
tion of the need for structured preventive strategies to reduce the risk of CVD in patients with 
rheumatic disease. Such strategies should be based on insights into the role of inﬂ  ammation 
in CVD, as well as optimal management of life style related risk factors. In this review, the 
research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic 
disorders is discussed.
Keywords: rheumatoid arthritis, systemic lupus erythematosus, cardiovascular disease, 
inﬂ  ammation
Introduction
Rheumatic diseases lead to chronic disability and reduced quality of life in many 
patients. Rheumatoid arthritis (RA), which is characterized by inﬂ  ammatory polyar-
thritis with progressive joint damage, occurs in about 0.5%–1% of the adult population 
in most countries (Silman and Hochberg 1993). The spectrum of chronic rheumatic 
disorders also includes spondyloarthropathies such as ankylosing spondylitis (AS), 
psoriasis associated arthropathies, and autoimmune syndromes such as systemic lupus 
erythematosus (SLE), systemic sclerosis and systemic vasculitides. Osteoarthritis 
(OA) is by far the most common chronic joint disease, and it is increasingly being 
recognized as a major contributor to the overall health burden in the society (Hootman 
et al 2006).
In addition to their impact on quality of life, RA and SLE are associated with an 
increased mortality compared to the general population (Gabriel et al 2003; Doria 
et al 2006). A major part of the excess mortality has been attributed to cardiovascular 
disease (CVD) (Jacobsson et al 1993; Manzi et al 1997). Suggested explanations for 
this pattern of CVD-related morbidity and mortality include a direct impact of chronic 
inﬂ  ammation (Sattar and McInnes 2005) and secondary effects of physical inactiv-
ity (Minor et al 1996; Turesson et al 2007b) and drugs used in the management of 
these diseases, including corticosteroids and nonsteroidal anti-inﬂ  ammatory drugs 
(NSAIDs) (Turesson et al 2007b). Similarities and differences in patterns of vascular 
morbidity between patients with RA and SLE may reﬂ  ect important concepts in the Vascular Health and Risk Management 2008:4(3) 606
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pathophysiology of atherosclerosis and autoimmune features 
in this process (Chogle and Chakravarty 2007). There is need 
for research on optimal preventive strategies for CVD in 
such patients (Chogle and Chakravarty 2007). In this review, 
we examine the evidence of risk for CVD in patients with 
rheumatic diseases and the suggested underlying mecha-
nisms, and discuss potential strategies for the prevention of 
CVD in such patients.
Epidemiology of CVD in patients 
with rheumatic diseases
SLE is associated with a substantially increased risk of coro-
nary artery disease, in particular in premenopausal women 
(Manzi et al 1997). There is also an increased risk of stroke 
in patients with SLE (Esdaile et al 2001), partly explained by 
co-existing antiphospholipid antibody syndrome in a subset 
of the patients. Patients with RA also have an increased 
incidence of CVD (Wållberg-Jonsson et al 1997; Solomon 
et al 2003).
The magnitude of this increase varies in different stud-
ies due to differences in case selection and the comparator 
population. In a community based RA cohort from southern 
Sweden, the risk of ﬁ  rst ever CVD events was estimated to be 
increased by 60%, mainly because of an excess of myocar-
dial infarctions (MI) (Turesson et al 2004b) (Figure 1). The 
incidence of MI has been found to be increased to a similar 
extent in men and women with RA (Turesson et al 2004b). 
By contrast, the risk of stroke in this (Turesson et al 2004b) 
or other RA populations (Solomon 2003) was not signiﬁ  -
cantly increased. This suggests that RA associated vascular 
abnormalities may speciﬁ  cally predispose to coronary artery 
disease, and not to cerebrovascular events, for which other 
risk factors, such as hypertension, may be more important.
There is also some evidence for an increased overall 
mortality and CVD mortality in patients with other rheumatic 
diseases such as AS (Lehtinen 1993), although the available 
data are limited. The same holds true for psoriatic arthritis 
(Wong et al 1997), but selection bias may be a particular 
problem in studies of clinical cohorts with this heterogeneous 
disease (Bond et al 2005). Subclinical atherosclerosis may 
be more frequent in patients with psoriatic arthritis than in 
the general population (Gonzales-Juanatey et al 2007). In a 
population-based study from Finland, ﬁ  nger joint OA was 
associated with an increased mortality from CVD in men, 
but not in women (Haara et al 2003). By contrast, there was 
no signiﬁ  cantly increased rate of vascular events or all-cause 
mortality in patients with OA overall in the UK General Prac-
tice Research Database (Watson et al 2003). Interestingly, in 
a long term population based survey of the Pima Indians in 
Arizona, USA, the presence of two or more swollen joints 
was a signiﬁ  cant predictor of CVD mortality, independent 
of traditional risk factors (Jacobsson et al 2001). This effect 
was seen also in subjects without a diagnosis of RA, when 
studied separately, suggesting that joint swelling of various 
causes may be associated with CVD.
Inﬂ  ammation and cardiovascular 
disease
Atherosclerosis is an inflammatory disorder, in which 
factors such as inflammation related dyslipidemia and 
chronic immune dysregulation contribute to the pathogenesis 
(Scherer and Shoenfeld 2006). The inﬂ  ammatory biomarker 
Figure 1 Cardiovascular morbidity in a community-based RA sample, compared with the general population. Standardized morbidity ratios; 95% conﬁ  dence intervals. Based 
on data from Turesson et al 2004.
Abbreviations: AMI, acute myocardial infarction; RA, rheumatoid arthritis.Vascular Health and Risk Management 2008:4(3) 607
Rheumatic diseases and CVD
high-sensitivity C-reactive protein (hs-CRP) predicts 
cardiovascular events in the general population (Ridker et al 
2004), and higher levels of hs-CRP indicate a poor prognosis 
in acute coronary syndromes (Ridker et al 2004). Carotid 
artery intima-media thickness (IMT), a measure of early 
atherosclerosis, correlates with circulating markers of systemic 
inﬂ  ammation in patients with RA as well as in subjects 
without the disease (Del Rincon et al 2003). In women with 
SLE, increased IMT has been associated with a higher total 
SLE organ damage score (Manzi et al 1999), indicating 
that atherosclerosis may be regarded as an effect of the 
inflammatory burden in patients with SLE and other 
rheumatic diseases. A recent study of surgical specimens 
from the aorta, taken from patients undergoing coronary 
artery bypass grafting, revealed a higher frequency of 
inﬂ  ammatory inﬁ  ltrates in the media and the adventitia of 
patients with inﬂ  ammatory rheumatic disorders (including 
RA, SLE and various vasculitides) compared to other patients 
(Hollan 2007). Diffuse vascular inﬂ  ammation in such patients 
may contribute to the development of atherosclerosis and 
possibly aneurysm formation. In addition, a number of more 
speciﬁ  c shared disease mechanisms in systemic rheumatic 
inﬂ  ammation and atherosclerotic vascular disease have been 
suggested (Table 1).
Atherosclerotic plaque formation 
and hemostasis
There is extensive evidence for the importance of proin-
ﬂ  ammatory cytokines such as tumour necrosis factor (TNF) 
in the development and rupture of atherosclerotic plaques 
subsequently leading to cardiovascular events. This is of 
particular interest to this topic, since TNF is also a key factor 
in the pathogenesis of RA, and a target for speciﬁ  c therapy 
with biologic agents such as monoclonal anti-TNF antibodies 
and soluble TNF receptor fusion proteins (Taylor 2003). The 
formation of the atherosclerotic plaque is enhanced by endo-
thelial activation, migration of monocytes into the vascular 
wall and scavenging of oxidized LDL (Ross 1999; Hansson 
2005), all of which are augmented by high levels of TNF 
(Dixon and Symmons 2007). Activation of these processes 
may lead to a vicious cycle promoting plaque growth. Tis-
sue studies have also shown that there is an abundance of 
inﬂ  ammatory cells at the border of atherosclerotic plaques, 
which probably promotes the rupture of the plaque with 
resultant cardiovascular events (Ross 1999; Hansson 2005; 
Dixon and Symmons 2007).
Inﬂ  ammation driven by proinﬂ  ammatory cytokines seems 
to be crucial for this process. It has for instance been shown 
that knockout of the TNF gene in atherosclerotic prone apoE 
knock-out mice inhibits growth of atherosclerotic plaques 
(Brånen et al 2004). Moreover, treatment with a soluble 
receptor for TNF resulted in a dose dependent inhibitory 
effect on the development of atherosclerosis in the same 
strain (Brånen et al 2004).
Furthermore, TNF and other cytokines activate the 
endothelium, which is reﬂ  ected by endothelial dysfunction 
and increased expression of adhesion molecules. In parallel, 
inﬂ  ammation contributes to a systemic up-regulation of pro-
teins involved in hemostasis. Patients with RA have increased 
serum levels of ﬁ  brinogen, von Willebrand factor and tissue 
plasminogen activator antigen compared with controls and 
these prothrombotic markers have been shown to predict 
cardiovascular events in patients with RA (McEntegart et al 
2001; Sattar et al 2003).
Immunology
Immunological pathways associated with chronic inﬂ  am-
mation are important in autoimmune diseases as well as 
in the development of CVD. The major histocompatibility 
complex (MHC) class II subtypes HLA-DR, -DQ and -DP 
are regulators of T-cell dependent immune responses, and 
aberrant expression of these tissue antigens in the endothe-
lium has been demonstrated in autoimmune diseases such 
as RA and SLE (Turesson 2004a). Recent data suggest an 
Table 1 Shared disease mechanisms in rheumatic diseases and 
CVD
Mechanism Pathway in vascular 
disease
References
Cytokine-induced 
macrophage migration and 
activation
Ox-LDL scavenging and 
formation of vulnerable 
atherosclerotic plaque
Ross 1999
Hansson 2005
Dixon and 
Symmons 2007
Cytokine-induced upregula-
tion of procoagulant factors
Increased systemic 
thrombodiatesis
McEntegart et al 
2001; Sattar et al 
2003
Systemic endothelial activa-
tion with upregulation of 
MHC class II molecules
Endothelial dysfunction
Increased T-cell migra-
tion and activation
Vallbracht et al 
2002; Turesson 
2004
Clonal expansion and activa-
tion of abnormal T-cells
Cytotoxicity leading 
to plaque damage 
Local cytokine 
upregulation
Park et al 1997
Liuzzo et al 1999
Michel et al 2007
Toloza et al 2004 Anti-phospholipid 
antibodies
Increased arterial and 
venous thrombodia-
tesis
Abbreviations: CVD, cardiovascular disease; LDL, low density lipoprotein; MHC, 
major hisocompatibility complex.Vascular Health and Risk Management 2008:4(3) 608
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association between such endothelial expression and diffuse 
endothelial dysfunction (Vallbracht et al 2002). Increased 
endothelial MHC class II expression may also be important 
for the activation and migration of T-cells and monocytes 
into the vascular wall.
In a chronic inﬂ  ammatory environment, T-cells may 
feature particular phenotypes, such as lack of surface expres-
sion of the co-stimulatory molecule CD28 (Schmidt et al 
1996). Increased levels of CD4+CD28null T-cells have been 
demonstrated in patients with chronic inﬂ  ammatory disor-
ders such as RA (Schmidt et al 1996), especially those with 
severe, systemic disease (Michel et al 2007), and unstable 
coronary artery disease (Liuzzo et al 1999). These T-cells are 
characterized by high production of IFN-γ (Park et al 1997), 
cytotoxic capabilities, and expression of natural killer cell 
markers including CD56 (Michel et al 2007) and killer immu-
noglobulin-like receptors. CD4+CD28null T-cells can also 
be isolated from culprit lesions in unstable coronary artery 
plaques (Liuzzo et al 2000) but not from stable plaques and 
have in addition been shown to correlate with intima-media 
thickness and impaired arterial ﬂ  ow mediated vasodilatation 
in RA (Gerli et al 2004).
Taken together, these data suggest a role for such cells 
in explaining the association between autoimmune vascular 
disease and CVD. The concept of modulation of such 
pathomechanisms by potent anti-inﬂ  ammatory treatment, 
such as TNF inhibitors, is supported by the observed up-
regulation of CD28 expression on T-cells in patients with RA 
treated with the monoclonal anti-TNF antibody inﬂ  iximab 
by Bryl and colleagues (2005). In addition, in a recent 
study of CD4+CD28null T-cells isolated from patients with 
unstable angina, such cells were depleted in vitro when the 
inﬂ  iximab was added to whole blood samples, suggesting that 
the persistence of this T-cell phenotype is TNF-dependent 
(Rizello et al 2006).
Risk factors for cardiovascular 
events in patients with rheumatic 
diseases
Traditional risk factors for vascular disease, such as smoking, 
hypertension, diabetes and hyperlipidemia, are important in, 
but do not fully account for, the increased risk of CVD in 
subjects with SLE (Esdaile et al 2001) or RA (Solomon et al 
2004a). Although there is an association between smoking 
and RA (Silman et al 1996) and SLE (Bengtsson et al 2002), 
the excess CVD morbidity and mortality in these disorders 
has been shown to be independent of smoking (Manzi et al 
1997; Maradit-Kremers et al 2005).
Disease severity has consistently been associated with an 
increased risk of CVD events in RA (Table 2). Disability, as 
measured by the Health Assessment Questionnaire (HAQ) 
(Fries et al 1982), has been shown to be a predictor of overall 
mortality (Wolfe et al 2003; Young et al 2007), CVD mortality 
(Young et al 2007), increased atherosclerosis (Kumeda et al 
2002) and CVD events (Jacobsson et al 2005). Patients with 
severe extra-articular RA manifestations are at an increased 
risk of developing coronary artery disease (Turesson et al 
2007a) as well as peripheral vascular disease (Liang et al 
2006); and severe extra-articular RA is a predictor of both 
overall mortality (Gabriel et al 2003) and cardiovascular 
mortality (Maradit-Kremers et al 2005), indicating that 
systemic inﬂ  ammation is a major determinant of vascular co-
morbidity in RA. An elevated erythrocyte sedimentation rate 
(ESR) has been shown to predict CVD mortality in several RA 
populations (Wållberg-Jonsson et al 1999; Maradit-Kremers 
et al 2005), and baseline CRP was an independent predictor 
of cardiovascular death in an inception cohort of recently 
diagnosed inﬂ  ammatory polyarthritis (Goodson et al 2005). In 
contrast with the general population, a low body mass index 
(BMI), rather than obesity, has been associated with increased 
CVD in patients with RA (Kremers et al 2004; Escalante 
et al 2005). This most likely reﬂ  ects cachexia associated with 
Table 2 Risk factors for cardiovascular disease in patients with 
rheumatoid arthritis
Risk factor Predicted outcome References
Severe extra-
articular manifes-
tations
Total mortality
and CVD mortality
First-ever CVD events
New onset PAD or 
venous thromboem-
bolic events
Gabriel et al 2003
Maradit-Kremers et al 2005;
Turesson et al 2007; 
Liang et al 2006
Disability (HAQ 
score)
Total mortality
and CVD mortality
First-ever CVD events
Wolfe et al 2003
Young et al 2007
Jacobsson et al 2005
ESR (60 mm/h 
at least 3 times)
Last ESR
CRP
Smoking
Death from CVD
CVD events
Death from CVD
Death from CVD
New onset PAD
Maradit-Kremers et al 2005; 
Wållberg-Jonsson et al 1999;
Goodson et al 2005; 
Maradit-Kremers et al 2005; 
Liang et al 2006
Hypertension Death from CVD Wållberg-Jonsson et al 1999; 
Maradit-Kremers et al 2005
Low BMI Death from CVD Kremers et al 2004
Escalante et al 2005
Abbreviations: CVD, cardiovascular disease; HAQ, health assessment questionnaire; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BMI, body mass index; 
PAD, peripheral arterial disease.Vascular Health and Risk Management 2008:4(3) 609
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severe inﬂ  ammation. By contrast, in patients with active SLE, 
BMI, and total body fat tend to increase over time, although 
this may partly be due to treatment with high doses of corti-
costeroids (Kipen et al 1999).
In SLE, smoking, elevated CRP, and antiphospholipid 
antibodies predicted CVD events in a multiethnic US cohort 
of patients (Toloza et al 2004). However, in a Swedish study 
of women with SLE, dyslipidemia was more frequently found 
in patients with a history of CVD compared with controls 
without CVD, whereas there was no difference for smoking, 
hypertension, diabetes or obesity (Svenungsson et al 2001). 
Such discrepancies may be due to differences between ethnic 
groups, or methodological issues, including selection bias.
There are conﬂ  icting evidence on the prevalence of 
hypertension (McEntegart et al 2001; Solomon et al 2004b) 
and hyperlipidemia (Park et al 1999; McEntegart et al 2001; 
Solomon et al 2004b) among patients with RA. This issue 
is further complicated by the impact of corticosteroid treat-
ment on blood pressure and metabolism. Several studies of 
prevalent RA cases have shown an increased prevalence of 
former smokers, but not current smokers, compared with non-
RA controls (McEntegart et al 2001; Solomon et al 2004b). 
Studies of prevalent RA and SLE cohorts may, however, 
be prone to bias from left censorship, because of premature 
death in patients with a high risk of CVD, or selection bias, 
because of accumulation of patients with treated vascular 
disease. In our opinion, long term follow-up of inception 
cohorts or community based samples with prospectively 
collected data give the most reliable information on co-
morbidity and related risk factors. Future studies of CVD 
risk in patients with rheumatic diseases should include data 
on apolipoprotein levels as well as abdominal obesity, since 
the INTERHEART study and other surveys have suggested 
that the apoB/apoA1 ratio and the waist/hip ratio are actu-
ally better predictors of myocardial infarction than LDL 
cholesterol and BMI (Yusuf et al 2004).
In a recent survey of men with AS from Glasgow, Scot-
land, there was an increased number of smokers and a higher 
BMI compared with age-matched healthy controls (Divecha 
et al 2005). There were also signiﬁ  cantly higher CRP, IL-6, 
ﬁ  brinogen, and von Willebrand factor levels in the AS group. 
This suggests an unfavorable cardiovascular risk proﬁ  le in 
AS, including systemic inﬂ  ammation that may predispose 
to CVD. A similar pattern probably exists in patients with 
psoriatic arthritis, where, in addition, dyslipidemia has 
been reported by several investigators (Peters et al 2004). 
In a study of patients with moderately severe to end-stage 
lower extremity OA, cases were found to have signiﬁ  cantly 
greater mean BMI, waist-hip ratio, systolic blood pressure 
and fasting blood glucose, and a lower mean high density 
lipoprotein cholesterol than age and sex matched controls 
without OA (Philbin et al 1996). As expected, the patients 
with knee or hip OA reported less performed aerobic exercise 
than controls.
Preventive strategies
Traditional risk factors
Several different strategies for the prevention of CVD should 
be considered in patients with rheumatic disorders (Table 3). 
There is a strong rational for targeting traditional CVD risk 
factors in high risk groups, since the likelihood of preventing 
CVD on an individual level with such interventions is greater. 
Overall, there are three complementary approaches to reduc-
ing the risk of CVD co-morbidity in patients with rheumatic 
disorders by targeting traditional risk factors: 1) Screen 
patients for CVD risk factors regularly, and use treatment 
targets recommended for the general population; 2): Use 
modiﬁ  ed targets closer to those recommended for other high 
risk groups (eg, patients with diabetes); 3): Use a modiﬁ  ed 
risk score algorithm, taking into account the increased risk 
of CVD in patients with severe rheumatic disorders, and base 
treatment decisions on the individual risk score.
The ﬁ  rst option may lead to a substantial improvement in 
the management of many patients. Traditionally, rheumatolo-
gists and other physicians treating patients with rheumatic 
diseases have focused on their musculoskeletal problems and 
paid limited attention to CVD risk factors. The cardiovascular 
health of these patients can be substantially improved if the 
managing physician takes and acts upon a smoking history, 
determines blood pressure and lipid levels regularly and 
screens for diabetes. This advice assumes that resources for 
such interventions are available and that guidelines for risk 
factor screening are implemented. It can also be argued that 
since the excess risk of CVD in RA and SLE could not be 
explained by increased frequency of traditional risk factors 
(Esdaile et al 2001; Solomon et al 2003), target values should 
be no different than those set for the general population.
The high risk of premature death from CVD in patients 
with SLE or severe RA is analogous to diabetes mellitus. 
Based on this, Wajed and colleagues (2004) suggested 
target levels for patients with SLE including a systolic 
blood pressure of 130/80 mm Hg and LDL cholesterol 
of 2.6 mmol/L (whereas the current recommendations 
for individuals without excess CVD risk are 140/90 mm 
Hg and 3.0 mmol/L, respectively). Similar guidelines have 
been proposed for patients with RA (van Doornum et al Vascular Health and Risk Management 2008:4(3) 610
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2006). The value of adhering to these targets for managing 
traditional risk factors in patients with rheumatic diseases is 
only incompletely known, and forms an agenda for further 
investigation.
Risk assessment for CVD can be performed by applying 
decision algorithms such as the Framingham risk score 
(Wilson et al 1998) or the SCORE risk estimation system 
(Conroy et al 2003), which is recommended by the Euro-
pean Society for Cardiology. With theses algorithms, the 
increased risk of CVD in patients with, for example, SLE 
and co-existing antiphospholipid syndrome, or severe 
extra-articular RA, can be accounted for by classifying 
them as having a risk corresponding to existing CVD 
related organ damage, with a correspondingly lower thresh-
old for intervention. This strategy directs interventions to 
patients with higher absolute risk of CVD. Ideally, such 
a modiﬁ  ed strategy should be tested in controlled clini-
cal trials, and its use in practice subjected to a structured 
evaluation.
Physical activity
Overall, patients with RA and other chronic rheumatic 
diseases have a reduced level of physical activity com-
pared with the general population (Hootman et al 2003). 
A corresponding degree of inactivity is associated with a 
reduced life expectancy in the general population (Franco 
et al 2005). A number of studies conﬁ  rm that regular, vigor-
ous physical exercise is associated with a reduced mortality, 
in particular from CVD (Turesson et al 2007b). In the US 
Nurses’ Health Study, obesity (BMI  30 kg/m2) and a sed-
entary life style (exercise 1 hour/week) were independent 
predictors of coronary heart disease (CHD) (Li et al 2006). Of 
particular interest, even in women with a normal weight (BMI 
18.5–24.9 kg/m2), sedentary living was associated with an 
increased risk of CHD (relative risk 1.48; 95% CI 1.24–1.77, 
adjusted for a number of covariates, including smoking) (Li 
et al 2006). Physical ﬁ  tness thus likely has effects beyond 
those of weight reduction. Suggested mechanisms include 
reduced plasma ﬁ  brinogen levels (Lakka and Salonen 1993) 
and other positive rheologic effects of exercise (Eichner 
1990) that may potentially even reverse the negative impact 
of chronic low-grade inﬂ  ammation.
Although the beneﬁ  ts of regular physical exercise are well 
recognized, implementing this knowledge remains a chal-
lenge in the general population (Warburton et al 2006) and 
in patients with rheumatic diseases. Whereas structured day-
care rehabilitation programs have been reported to increase 
the number of self reported performed physical activities 
(Wikström and Jacobsson 2005), another intervention study 
directed at adverse life style factors in patients with estab-
lished RA led only to modest improvement (Gordon et al 
2002). The current overall trend in most populations is rather 
towards decreasing physical activity and weight gain. The 
growing epidemic of obesity in the US and other countries 
has been projected to lead to a rapidly increasing incidence 
of OA (Hootman and Helmick 2006), creating a vicious 
circle of inactivity, obesity and arthritis, likely contributing 
to CVD morbidity. Efforts to change this pattern and reduce 
life style related risk factors for CVD are of major impor-
tance. In patients with rheumatic disorders, patient education, 
physiotherapy and structured day-care or in-patient reha-
bilitation are tools to increase physical exercise. As all other 
interventions, they should be thoroughly evaluated.
Statin treatment
Statins (3-hydroxy-3-methylglutarylcoenzyme-A reductase 
inhibitors) reduce CVD morbidity and mortality (Ridker 
et al 2005). Although they were originally used in this 
context because of their effects on lipid levels, it has 
become increasingly evident that they have other actions 
which may diminish CVD risk. The anti-inﬂ  ammatory and 
immunomodulating effects of statins include suppression 
Table 3 Strategies for prevention of CVD in patients with 
rheumatic diseases
Preventive strategy Suggested interventions References
Achieve target levels 
for traditional risk 
factors including blood 
pressure, glucose, and 
lipids
Regular screening, 
counselling and 
pharmacotherapy according 
to guidelines
Wajed et al 2004
van Doornum 
et al 2006
Reduce traditional risk 
factors in high risk 
individuals
Interventions based on 
decision algorithms, guided 
by risk scores
Wilson et al 1998
Yusuf et al 2003
Increase physical 
exercise
Patient education, phys-
iotherapy and structured 
rehabilitation
Wikström et al 
2005; Turesson 
et al 2007b
Preventive statin treat-
ment
Statins for patients with 
severe RA, despite moder-
ate cholesterol levels
McCarey et al 
2004; van 
Doornum et al 
2004
Reduce inﬂ  ammatory 
burden in patients 
with RA
Use methotrexate as 
drug of choice in RA 
Add TNF inhibitor in 
refractory patients
Choi et al 2002
Jacobsson et al 
2005
Abbreviations: CVD, cardiovascular disease; RA, rheumatoid arthritis; TNF, 
tumor necrosis factor. Vascular Health and Risk Management 2008:4(3) 611
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of leukocyte cytokine release, reduced MHC class II 
expression and reduced production of reactive oxygen spe-
cies (Palinski and Napoli 2002). A low achieved hs-CRP 
level (2 mg/L) has been shown to be a good marker of 
reduced risk of recurrent MI or coronary death in patients 
hospitalized because of acute coronary syndromes and 
treated with atorvastatin or pravastatin (Ridker et al 2005). 
This suggests that the anti-inﬂ  ammatory properties of 
statins are clinically important.
Statin-related reduction in inﬂ  ammatory biomarkers 
provided the rationale for a randomized controlled trial of 
atorvastatin for treatment of synovitis in RA (the Trial of 
Atorvastatin in Rheumatoid Arthritis [TARA]) (McCarey 
et al 2004). There was a signiﬁ  cant reduction in CRP and 
ESR, as well as in the swollen joint count and the disease 
activity score, in patients treated with 40 mg atorvastatin daily 
for 6 months compared with placebo. A good or moderate 
clinical response (according to the European League Against 
Rheumatism criteria) was seen in 31% of patients treated 
with atorvastatin compared to 10% in the placebo group 
(p = 0.006). As expected, the anti-inﬂ  ammatory effect was 
paralleled by a substantial reduction in total cholesterol and 
LDL cholesterol. Apart from reducing lipid levels, treatment 
with statins in patients with RA may also have a modest but 
clinically useful effect on arthritis. Atorvastatin has also 
been shown to reduce arterial stiffness in patients with RA 
and high disease activity (van Doornum et al 2004). Taken 
together, these ﬁ  ndings may suggest a lower threshold for 
using statins in patients with RA.
The low cholesterol levels found in patients with active 
RA due to inﬂ  ammation (Rantapää-Dahlqvist et al 1991) 
indicate that target levels from general guidelines may 
not be adequate for RA populations. In a recent placebo-
controlled study of the effect of atorvastatin on markers of 
atherosclerosis in patients with SLE (the Lupus Atheroscle-
rosis Prevention Study [LAPS]), there was no signiﬁ  cant 
effect on the primary endpoints: the change in the coronary 
calcium score or the change in the carotid artery IMT (Petri 
et al 2006). It should be noted that this study excluded 
patients with hyperlipidemia for whom statin treatment 
would normally be indicated. Since surrogate markers are 
poor substitutes for hard CVD endpoints, additional studies 
in patients with SLE as well as RA are needed. Furthermore, 
although atorvastatin was well tolerated in the TARA study 
as well as in the LAPS, long term safety data in patients 
with rheumatic disorders are lacking. Based on the currently 
available data, we suggest that statins should be considered in 
patients with severe RA and an unfavorable CVD risk proﬁ  le, 
and that individual lipid or apolipoprotein level targets may 
need to be modiﬁ  ed.
Anti-rheumatic therapy
Corticosteroids are often used in the treatment of SLE, RA, 
and other inﬂ  ammatory disorders. High dose treatment with 
corticosteroids has adverse effects on the cardiovascular 
system, including endothelial dysfunction, hypertension and 
dysregulated glucose metabolism (Boots et al 2004). To our 
knowledge, there is no evidence for similar clinical effects in 
patients treated with moderate or low doses (7.5 mg/day). 
On the other hand, a protective effect from CVD could be 
postulated based on control of inﬂ  ammation. Indeed, in 
patients with SLE, it has been suggested that corticosteroid 
treatment may be associated with a reduced risk of athero-
sclerosis (Roman et al 2003). In RA, the net effect of low 
dose glucocorticoids is still not deﬁ  ned (Davis et al 2005). 
However, long term treatment with higher doses is likely to 
increase the risk of CVD, in addition to other side effects. 
In a recent report from a long term RA study, there was an 
interaction between the cumulative corticosteroid dose and 
RF status, with the highest risk for heart failure and death 
from CVD in RF positive patients receiving high doses over 
extended time periods (Davis et al 2007). The mechanisms 
underlying this relationship are unknown. Since the study 
included patients recruited between 1955 and 1995, it is not 
clear whether the results are applicable to patients receiving 
modern DMARD therapy from disease onset.
Recently, the risk of adverse vascular events associated 
with treatment with cyclooxygenase (COX) inhibitors, 
in particular selective COX-2 inhibitors, has been recog-
nized. Based on a signiﬁ  cant increase of CVD events in a 
randomized trial, rofecoxib has been withdrawn from the 
market, while other coxibs and traditional non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs) may have less impact 
on the risk of CVD (Solomon et al 2006a).
In a survey of elderly individuals in the Pennsylvania 
Medicare database, where use of rofecoxib, but not of cele-
coxib, was associated with increased risk of CVD, a diagnosis 
of RA remained a signiﬁ  cant predictor of CVD mortality in 
an analysis adjusted for traditional risk factors and NSAID 
treatment (Solomon et al 2004a). In an extension of this 
study, except for the conﬁ  rmed association with rofecoxib, 
no signiﬁ  cantly increased risk of MI in patients with RA 
using COX-inhibitors compared to non-users was detected 
(Solomon et al 2006b). It is unlikely therefore that the use of 
COX-inhibitors is the main reason for the observed increased 
risk of CVD in patients with RA.Vascular Health and Risk Management 2008:4(3) 612
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A growing body of evidence indicates that traditional 
NSAIDs as well as coxibs have some impact on development 
of CVD in patients with RA and OA (Kearney et al 2006). 
In a large, recent trial, there was no signiﬁ  cant difference in 
the occurrence of hard CVD endpoints between diclofenac 
(150 mg/day) and etoricoxib (60 or 90 mg/day), whereas 
discontinuation due to hypertension was more frequent 
among those treated with etoricoxib (Cannon et al 2006). 
Presently, a careful evaluation of the cardiovascular risk 
in the individual patients should precede the use of COX-
inhibitors, and further studies attempting to estimate the 
relative impact of different agents should be performed. In 
addition, further observational studies of CVD in patients 
with rheumatic disorders should take the impact of COX-
inhibitors into account.
Finally, consistent with the concept that disease activity 
as well as severity determines the risk of CVD in RA, treat-
ment with methotrexate has been associated with a reduced 
cardiovascular mortality in a large observational study 
(Choi et al 2002). Recently, treatment with TNF inhibitors 
was associated with a lower risk of ﬁ  rst-ever CVD events 
in a study of community based RA registers in Sweden 
(Jacobsson et al 2005). Additional follow-up of this cohort 
has revealed a reduced overall mortality in RA patients 
treated with TNF inhibitors, in particular among those with 
extensive disability indicated by high HAQ scores (Jacobsson 
et al 2007). A recent report from a survey of Spanish registers 
also reported a survival beneﬁ  t from treatment with TNF 
inhibitors (Carmona et al 2007).
These ﬁ  ndings contrast with the disappointing results 
from randomized controlled trials of treatment of established 
congestive heart failure (CHF) with the TNF inhibitors inﬂ  ix-
imab and etanercept. Especially noteworthy was an increased 
mortality rate associated with the administration of high dose 
of inﬂ  iximab in patients with severe CHF (New York Heart 
Association class III and IV) (Anker et al 2002). Since the 
available data suggest that TNF inhibition in RA does not 
lead to an increased risk for developing CHF in RA patients 
(Wolfe et al 2004), it is likely that this negative effect is 
conﬁ  ned to patients already suffering from severe established 
CHF. The latter is therefore regarded as a contraindication for 
treatment with TNF inhibitors. Finally, although treatment 
with TNF blockers have a substantial effect on signs and 
symptoms in patients with severe AS and psoriatic arthritis, 
the long term effect on CVD co-morbidities in such patients 
has not been evaluated.
The reduced CVD morbidity and mortality associated 
with potent anti-inﬂ  ammatory treatment in patients with RA 
could be partly due to a direct effect on the inﬂ  ammatory 
burden, and partly due to reduced disability and increased 
physical activity. From a cardiovascular disease standpoint, 
management of rheumatic disorders should aim at disease 
modiﬁ  cation and, ideally, remission. Such treatment would 
also reduce the need for treatment with NSAIDs and corti-
costeroids and their attendant CVD risks.
Conclusions
Patients with rheumatic disorders have an increased risk 
of CVD morbidity and premature mortality. This is to a 
major extent due to the chronic inﬂ  ammatory burden and to 
reduced physical activity. Suppression of inﬂ  ammation by 
potent anti-rheumatic drug treatment, such as TNF inhibitors 
for patients with RA, can reduce the risk of CVD events. 
Additional preventive strategies include regular screening for 
and intervention against traditional risk factors, preventive 
treatment with statins and efforts to increase regular physi-
cal exercise. Scientiﬁ  c evaluation of such interventions is of 
major importance. The shared disease mechanisms in chronic 
rheumatic disorders and atherosclerotic vascular disease are 
a ﬁ  eld for further fruitful investigation.
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